Biobeat already integrated into 14 Israeli isolation departments for COVID-19 patients

Biobeat, an end-to-end medical grade monitoring system for the management of patients and individuals from a distance is currently being utilised in 14 Israeli hospitals as the main monitoring solution in COVID-19 isolation units as part of the effort by the Israeli Ministry of Health to combat

...

SwRI receives $9.9 million to develop nerve agent antidote

Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health.

The use of nerve agents continues to be

...

Inovio Receives $5M Grant for COVID-19 Vaccine Delivery Device

INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for

...

Updated COVID-19 Resources

The  Disaster Information Management Research Center ...

ERVEBO Now Registered in Four African Countries

Merckhas confirmed that ERVEBO has now been registered by National Health Authorities in the following countries in Africa – DRC, Burundi, Ghana, and Zambia. 

ERVEBO was granted a conditional marketing authorization by the European Commission on November 11, 2019 and approved by

...

Irish Innovation in Wipes and Masks Could Help Battle Emerging Coronavirus Crisis

“What we have developed is like a living Velcro that removes and traps pathogens”

Nature-inspired wipes and masks which could capture and trap the Wuhan Coronavirus (2019-nCoV) are being developed by scientists at the Irish company Aquila Bioscience. This technology can be used

...

CEPI grants $9M to Inovio to develop coronavirus vaccine

Inovio Pharmaceuticals, USA has announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's

...

Elmon Release CBRN Suit

Elmon  is a leading manufacture of Ballistic (bulletproof) protection. For the last five years Elmon have been working on developing and adding CBRN suits to be included with its products, and are proud about the launching their very own CBRN protection suite with respirator,

...

Ebola vaccine safety to be studied 5 years post vaccination

The Partnership for Research on Ebola Vaccination (PREVAC) has launched a project called PREVAC-UP with the aim of evaluating three Ebola vaccine regimens for five years after vaccination.

The study will assess several factors of these treaments

  • long-term
...

Pentagon Presses for Access to Special EU Defense Projects

David Norquist, the U.S. Deputy Defense Secretary, has said that American Defense firms should not be cut out of European Union programs to strengthen its industrial base, such as the European Defence Fund and the Permanent Structured Cooperation program. 

Speaking at the

...

Merck's Ebola Vaccine Granted Conditional Approval in the EU

Merck , known as MSD outside the United States and Canada, today announced that the European Commission has granted a conditional marketing authorization to ERVEBO for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola

...

Avon Protection General Service Respirator now in service with UK MOD

Avon Protection is pleased to announce that the UK MOD General Service Respirator (‘GSR’) is now in production and work has begun to deliver the first order.

Avon Protection was awarded the 5-year contract to resupply and in-service support for the GSR in February 2018. After a year of

...

GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic

GlaxoSmithKline plc has announced the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.

The decision to divest these brands, acquired from Novartis in 2015 as

...

FDA Clears First Rapid Diagnostic Test for Ebola

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) on Thursday allowed the marketing of the first rapid diagnostic test for the Ebola virus that has not been authorized via the agency’s Emergency Use Authorization (EUA) pathway.
...

NIOSH Releases First Responder Illicit Drug Toolkit

The National Institute for Occupational Safety and Health (NIOSH) has released a new virtual toolkit to help first responders reduce their exposure to fentanyl and other illicit drugs. The toolkit provides resources to help keep first responders safe when arriving on a scene where illicit

...

FLIR Aquires Tethered Drone Assets and Technology from Aria Insights

FLIR Systems, Inc. has announced that it has acquired the intellectual property (IP) and certain operating assets of Aria Insights, Inc. Terms of the deal are not being disclosed.

Previously known as CyPhy Works, Inc., Aria pioneered the development of tethered small unmanned aerial

...

Ebola Therapy mAb114 Receives $14 million in Funding

It was annonuced on September 24th that the Biomedical Advanced Research and Development Authority (BARDA) intends to provide $14 millio, as well as expertise support for the advanced development of an investigational Ebola treatment being pursued by Ridgeback Biotherapeutics of

...

FDA Approve Smallpox/Monkeypox Vaccine

The FDA has approved the Jynneos vaccine by Bavarian Nordic for the prevention of Smallpox and Monkeypox in adults 18 years of age and older determined to be at high risk for these infections.

Jynneos is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic

...

MCDC Award $20 Million Contract for Development of Auto-Injector

Emergent BioSolutions Inc.  announced on September 25th that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being designed for intramuscular

...

Biofactura Awarded $67.4 Million to Develop Smallpox Biodefense Therapeutic

BioFactura, Inc. announced on September 26th a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment

...

LLNL Nerve Agent Antidote Shows Great Potential

Scientists at the Lawrence Livermore National Laboratory have been working with live agent, supercomputers, and accelerated mass spectrometry, to develop a new nerve agent antidote, namely LLNL-02. 

Their work has been showing great promise, and with somw refinement of

...

HHS Purchases Additional Smallpox Vaccine for SNS

The U.S. Department of Health and Human Services (HHS) announced this week that they will be purchasing a smallpox vaccine, called ACAM2000, to build and replenish vaccine stored in the ...

HHS Funds an Additional Year of Ebola Vaccine Manufacturing

As part of the international response to the Ebola virus outbreak in the Democratic Republic of the Congo (DRC) and to meet domestic biodefense goals, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will support

...

GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study

GeoVax Labs, Inc.has announced positive results (100% protection) from preclinical challenge studies of its Marburg virus vaccine candidate; Marburg virus a critical medical threat against which there is currently no available vaccine or treatment. This study data adds to that showing similar

...

SIGA Awarded DOD Contract for Development of TPOXX as PEP for Smallpox

SIGA Technologies announced today that they have been awarded a multi-year contract by the U.S. Department of Defense (DOD) to support the work necessary to gain a potential label expansion for TPOXX that would include its use for post-exposure prophylaxis (PEP) for Smallpox.

The

...

OPCW report on Pueblo Chemical Agent-Destruction Pilot Plant

The OPCW has been visiting and reporting on the progress at the Pueblo Chemical Agent-Destruction Pilot Plant (PCAPP), in pursuance with decision C-16/DEC.11 “Final Extended Deadline of 29 April 2012”. 

 

The latest report from the OPCW visit in April 2019 is

...

Bavarian Nordic launch phase 3 trial of Smallpox vaccine

Bavarian Nordic announced on June 19 the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects. 

Ology Bioservices Wins Two DOD Awards Totalling More Than $135 Million

Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through its Platforms for Rapid Integrated Solutions for Medical Countermeasures (PRISM) office, has awarded the company with two contracts

...

AntoXa awarded contract for anti-nerve agent enzyme

AntoXa Corporation has been awarded a contract with the Government of Canada to continue work on production of plant-made butyrylcholinesterase (BuChE), a protein that provides protection against toxic nerve agents such as sarin and soman.

The one-year contract, worth up to

...

Avon Protection Awarded $254m U.S Army Contract

The U.S Department of Defense has awarded Avon Protection Systems a contract worth $245m for the production of the M53A1 respirator. 

The M53A1 was developed by Avon to counter military unique and domestic threats encountered on the modern battlefield, the global war on

...

$24.5 million to develop vaccines and therapies for Nipah and Hendra viruses

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), along with Uniformed Services University of the Health Sciences (USU), Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and

...

Our Current Sponsors